Kingworld Medicines Group Limited disclosed in its monthly return to Hong Kong Exchanges and Clearing Limited that there were no changes to its share capital for the month ended 31 July 2026.

The company’s authorised capital stayed at 10.00 billion ordinary shares with a par value of HKD 0.10 each, maintaining total authorised share capital of HKD 1.00 billion—unchanged from the previous month.

Issued share capital was likewise stable: 622.50 million ordinary shares remained in circulation, with no treasury shares outstanding and no issuances or cancellations reported during the period.

Kingworld Medicines affirmed that it met the Main Board’s minimum 25% public-float requirement as of 31 July 2026.

No activity occurred under share option schemes, warrants, convertible securities, or other share-issuance arrangements.

The return, filed on 4 August 2026, was signed by Director Zhou Xuhua.